Back

Incremental cardiovascular benefit of GLP-1RA added to SGLT2i in type 2 diabetes: a target trial emulation in the US veterans health administration

30 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Cardiometabolic pharmacotherapy in complex settings Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Julio Alejandro Lamprea Montealegre

UCSF Medical Centre, San Francisco (United States of America)

5 More presentations in this session

Presentation thumbnail
Effects of SGLT2i in the perioperative care of cardiac surgery: a systematic review and meta-analysis of randomised controlled trials
Mr K. Chagas (Itaperuna, BR)
Abstract Slides Video
Presentation thumbnail
Cardiovascular outcomes by baseline blood pressure control status in persons with type 2 diabetes at high cardiovascular risk treated with oral semaglutide
Professor N. Poulter (London, GB)
Abstract Slides Video
Presentation thumbnail
SGLT2-inhibitors in diabetic patients with severe aortic stenosis and extra-valvular cardiac damage undergoing TAVI
Doctor G. Vincelli (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Cardiovascular and economic outcomes of combined liraglutide and empagliflozin therapy in type 2 diabetes: a 6-year study
Doctor I. Thymis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Tirzepatide versus dulaglutide in type 2 diabetes: a comparative meta-analysis of cardiometabolic outcomes and safety
Mr J. Maldonado Flores (Tijuana, MX)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiometabolic pharmacotherapy in complex settings

The Event

Event poster

ESC Congress 2026

30 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Prevention of incident atrial fibrillation in type 2 diabetes: nationwide target trial emulation of SGLT2 inhibitors versus GLP-1 receptor agonists
28 August 2026
thumbnail
Congress Presentation
Cardiovascular and renal outcomes of Semaglutide in patients with Type 2 Diabetes Mellitus with established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease: A Meta-Analysis
31 August 2026
thumbnail
Congress Presentation
Beta blockers and renin-angiotensin-aldosterone system inhibitors after type 2 myocardial infarction, a target trial emulation study
30 August 2026
thumbnail
Congress Presentation
Cardiovascular outcomes across GLP-1/GIP agonists in a large, diverse real-world cohort: the INCRETIN-CV study
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources